The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

Nature Medicine

Volumn 6, Issue 9, 2000, Pages 1004-1010

  Kureishi, Yasuko ^a   Luo, Zhengyu ^a   Shiojima, Ichiro ^a   Bialik, Ann ^a   Fulton, David ^b   Lefer, David J ^c   Sessa, William C ^b   Walsh, Kenneth ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE SYNTHASE; PROTEIN KINASE; PROTEIN KINASE AKT; SIMVASTATIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SIGNAL TRANSDUCTION;

ANIMAL; CHOLESTEROL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HINDLIMB; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC-OXIDE SYNTHASE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RABBITS; SIGNAL TRANSDUCTION; SIMVASTATIN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033826581     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/79510     Document Type: Article

References (36)

1. Goldstein, J.L & Brown, M.S. Regulation of the mevalonate pathway. Nature 343, 425-430 (1990).
2. ScandinavianSimvastatinSurvivalStudyGroup. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study(4S). Lancet 344, 1383-1389 (1994).
3. Levine, G.N., Keaney Jr., J.F. & Vita, J.A. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N. Engl. J. Med. 332, 512-521 (1995).
4. Sacks, F.M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001-1009 (1996).
5. WestofScotlandCoronaryPreventionStudyGroup. Influence of pravastatin and plasma lipids of clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulatior 97, 1440-1445 (1998).
6. Endres, M. et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 95, 8880-8885 (1998).
7. Lefer, A.M. etal Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100, 178-184 (1999).
8. Pruefer, D., Scalia, R. & Lefer, A.M. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 19, 2894-2900 (1999).
9. Osborne, J.A., Siegman, M.J., Sedar, A.W., Mooers, S.U. & Lefer, A.M. Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits. Am. J. Physiol. 256(3 Pt 1), C591-C597 (1989).
10. Lefer, A.M. & Lefer, D.J. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion. Cardiovasc. Res. 32, 743-751 (1996).
11. Dupuis, J., Tardif, J.-C., Cernacek, P. & Théroux, P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation 99, 3227-3233 (1999).
12. Baller, D. et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 99, 2871-2875 (1999).
13. Datta, S.R., Brunet, A. & Greenberg, M.E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905-2927 (1999).
14. Gerber, H.-P. et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343 (1998).
15. Fujio, Y. & Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 274, 16349-16354 (1999).
16. Kim, I. et al. Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Circ. Res. 86, 24-29 (2000).
17. Kontos, C.D. et al. Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol. Cell. Biol. 18, 4131-4140 (1998).
18. Papapetropoulos, A. et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/Survivin pathway. J. Biol. Chem. 275, 9102-9105 (2000).
19. Carmeliet, P. et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98, 147-157 (1999).
20. Fujio, Y., Nguyen, T., Wencker, D., Kitsis, R.N. & Walsh, K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 101, 660-667 (2000).
21. Fulton, D. et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399, 597-601 (1999).
22. Dimmeler, S. et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605 (1999).
23. Luo, Z. et al. Acute modulation of endothelial Akt/PKB activity alters NO-dependent vasomotor activity in vivo. J. Clin. Invest., In press. (2000).
24. Morales-Ruiz, M. et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ. Res. 86, 892-896 (2000).
25. Benjamin, L.E., Golijanin, D., ltin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
26. Alon, T. et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature. Med. 1, 1024-1028 (1995).
27. Ziche, M. et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest. 99, 2625-2634 (1997).
28. Murohara, T. et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101, 2567-2578 (1998).
29. Pu, L.Q. et al. Angiogenic growth factor and revascularization of the ischemic limb: evaluation in a rabbit model. I. Surg. Res. 54, 575-583 (1993).
30. Simon, D.I. et al. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler. Thromb. 13, 791-799 (1993).
31. Qian, H.S., Neplioueva, V., Shetty, G.A., Channon, K.M. & George, S.E. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation 99, 2979-2982 (1999).
32. von der Leyen, H.E. et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. USA 92, 1137-1141 (1995).
33. Guo, K., Andrés, V. & Walsh, K. Nitric oxide-induced downregulation of cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells. Circulation 20, 2066-2072 (1998).
34. Laufs, U. & Liao, J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271 (1998).
35. Kaesemeyer, W.H., Caldwell, R.B., Huang, J. & Caldwell, R.W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Amer. Coll. Cordiol. 33, 234-241 (1999).
36. TASCWorkingGroup. Investigation of patients with intermittent claudication. J. Vasc. Surg. 31 (Suppl.), S62-S66 (2000).